GlassScriptPhysician profile
Aruna Arekapudi
NPI 1811992852
$4,955.77
in general payments reported to CMS, 2019-2025
55 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $589 · 2021: $738 · 2022: $812 · 2023: $587 · 2024: $468 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.51 |
| Education | $276.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $579.59 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $424.76 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $302.57 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $291.41 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $241.98 | 2019-2025 | |
| Celgene Corporation | $207.87 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $193.95 | 2019-2023 | Piqray, Kisqali |
| Pharmacyclics LLC, An Abbvie Company | $189.00 | 2019-2022 | |
| Daiichi Sankyo INC. | $182.15 | 2020-2025 | Enhertu, Vanflyta |
| Eisai INC. | $154.02 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $134.79 | 2019-2025 | Opdivo |
| Incyte Corporation | $124.42 | 2020-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $122.32 | 2020-2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $119.06 | 2020-2023 | Imfinzi, Enhertu |
| Genentech USA, INC. | $117.40 | 2019-2023 | Venclexta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Arekapudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.